Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drugging histone methyltransferases in cancer.

Current opinion in chemical biology - 1 Jun 2020

Richart Laia, Margueron Raphaël

Abstract excerpt

Targeting chromatin-modifying enzymes is a promising strategy for cancer treatment. The antitumor effectivity of compounds inhibiting histone methyltransferases - mainly EZH2 - is currently being tested in phase I/II clinical trials, some of them showing positive results in hematological malignancies and solid tumors of specific mutational background. In this review, we aim at highlighting the recent advances in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinogenesis
Share to Chromatin
Share to Drug Design

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Enhancer of Zeste Homolog 2 Protein

Share to Enzyme Inhibitors

Share to Histone Methyltransferases

Share to Methylation

Source

Identifiers

PMID: 31981999
DOI: 10.1016/j.cbpa.2019.11.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drugging histone methyltransferases in cancer.PMID 31981999Read ↗

Epigenetic Therapy: Histone Acetylation, DNA Methylation and Anti-Cancer Drug DiscoverySemantic proximity Read ↗

Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).Semantic proximity Read ↗

The biology of novel dual histone methyltransferase inhibitorsSemantic proximity Read ↗

Therapeutic targeting of chromatin: status and opportunities.Semantic proximity Read ↗

Cancer treatment of the future: inhibitors of histone methyltransferases.Semantic proximity Read ↗

Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effectsSemantic proximity Read ↗

Nucleosidic DNA demethylating epigenetic drugs – A comprehensive review from discovery to clinicSemantic proximity Read ↗

Mutations in Epigenetic Modifiers in Myeloid Malignancies and the Prospect of Novel Epigenetic-Targeted TherapySemantic proximity Read ↗

DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studiesSemantic proximity Read ↗

DNA Methylation–Targeted DrugsSemantic proximity Read ↗

Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical developmentSemantic proximity Read ↗

Epigenetics and OncologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.